The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...

Researchers discovered a promising leukemia drug breakthrough that could help patients overcome treatment resistance, ...

Serum interleukin-6, cardiovascular disease, and mortality in chronic lymphocytic leukemia. Background: Secondary AML (sAML) is a well recognized poor prognostic factor in AML. sAML is a heterogeneous ...

Moleculin Biotech ( (MBRX)) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to ...

DUBLIN--(BUSINESS WIRE)--The "Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends" report has been added to ResearchAndMarkets.com's offering. The global AML treatment market was ...

AB Science SA (Euronext - FR0010557264 - AB) today provides an update on the Phase 1 study of the molecule AB8939 and the fourth consecutive response with the combination of AB8939 + venetoclax in ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Moleculin Biotech ( (MBRX)) has ...

New developments in the complex and rapidly changing world of acute myeloid leukemia (AML) promise to improve health outcomes for people with the disease. They include: Advances in diagnostics ...

Tatiana Schlossberg, President John F. Kennedy's granddaughter, has died. Here's what to know about acute myeloid leukemia ...

Panelists discuss how social determinants of health significantly impact AML care, particularly regarding transportation access, health literacy, and the intensive nature of treatment requiring ...